Skip to main content

Rucsanda Pinteac

Institutions of which they are part

Postdoctoral researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Rucsanda Pinteac

Institutions of which they are part

Postdoctoral researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Projects

Búsqueda de compuestos que bloquean la acción de la chitinase 3-like 1 sobre las neuronas como tratamiento para los pacientes con esclerosis múltiple

IP: Manuel Comabella Lopez
Collaborators: Rucsanda Pinteac , Elisa Marín Ordovás
Funding agency: Instituto de Salud Carlos III
Funding: 233750
Reference: PI24/01088
Duration: 01/01/2025 - 31/12/2027

Modelos humanizados basados en células madre pluripotentes inducidas para estudiar la patología oligodendroglial y estrategias de remielinización en pacientes con esclerosis múltiple

IP: Andres Miguez Gonzalez
Collaborators: Modelos humanizados basados en células madre pluripotentes inducidas para estudiar la patología oligodendroglial y estrategias , Rucsanda Pinteac , Elisa Marín Ordovás
Funding agency: Instituto de Salud Carlos III
Funding: 140000
Reference: PI24/01117
Duration: 01/01/2025 - 13/03/2025

Human induced pluripotent stem cell-based chimeric mice to study astrocyte pathology and neuroprotective strategies in multiple sclerosis patients

IP: Manuel Comabella Lopez
Collaborators: Rucsanda Pinteac , Andres Miguez Gonzalez
Funding agency: Instituto de Salud Carlos III
Funding: 286770
Reference: PI21/01611
Duration: 01/01/2022 - 30/06/2025

Liquid biopsy in multiple sclerosis: A non-invasive approach for disease prognosis and drug discovery...

IP: -
Collaborators: Jordi Rio Izquierdo, Ana Zabalza de Torres, Rucsanda Pinteac
Funding agency: Instituto de Salud Carlos III
Funding: 140360
Reference: PI20/01697
Duration: 01/01/2021 - 30/06/2025

Related news

An international study led by researchers from Vall d’Hebron shows that simple tests that patients can perform themselves help detect changes in disability that may occur even in the absence of disease relapses.

A Vall d’Hebron study, carried out at Cemcat, shows that the risk of inflammatory activity increases after discontinuing treatment, but is considerably reduced in people over 60 years of age.

The project will analyse the functional activation of the NLRP3 inflammasome to advance the early identification of patients at risk of insufficient response to S1P receptor-modulating therapies.

Related professionals

Silvia Alarcón Portabella

Silvia Alarcón Portabella

Research assistant
Ophtalmology
Read more
Antonio Palasi Franco

Antonio Palasi Franco

Research technician
Neurovascular Diseases
Read more
Judith Martínez Lacambra

Judith Martínez Lacambra

Tècnic de recerca
Clinical Trials Management Unit
Commercial and Academic Clinical Research
Read more
Alicia Fresno González

Alicia Fresno González

Administration and Management
Cardiovascular Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.